The European Commission approved Adcetris (brentuximab vedotin) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) to treat adult patients with previously untreated CD30+ stage 3 Hodgkin lymphoma.
The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval a Type II variation for Rubraca (rucaparib), as a first-line maintenance treatment for all women with advanced ovarian cancer regardless of their BRCA mutation status, who have responded to first-line platinum-based chemotherapy.
Amid the gridlock that has seized Washington, NCI faces a grim and disturbing FY2024, the institute’s Principal Deputy Director Douglas R. Lowy said at the annual meeting of the Association of American Cancer Institutes.
As Robert A. Winn begins his two-year term as president of the Association of American Cancer Institutes, his presidential initiative of “Inclusive Excellence” aims to increase collaboration among cancer centers, their communities, and other cancer organizations in the United States and abroad.
The National Academy of Medicine (NAM) announced the election of 90 regular members and 10 international members during its annual meeting.
The Senate confirmation hearing for NCI Director Monica Bertagnolli, who has been nominated for the job of NIH director, has been scheduled for Oct. 18.
Katalin Karikó (left) and Drew Weissman (right)Photo credit: Niklas Elmehed © Nobel Prize OutreachKatalin Karikó and Drew Weissman were jointly awarded the 2023 Nobel Prize in Physiology or Medicine “for their discoveries concerning base modifications that enabled the development of effective mRNA vaccines against COVID-19.”
Moungi Bawendi (left), Louis Brus (center) and Alexei Ekimov (right)Photo credit: Niklas Elmehed © Nobel Prize OutreachMoungi G. Bawendi, Louis E. Brus, and Alexei I. Ekimov were jointly awarded the 2023 Nobel Prize in Chemistry for their discovery and development of quantum dots—nanoparticles so tiny that their size determines their properties. These smallest components of nanotechnology now spread their light from televisions and LED lamps, and can also guide surgeons when they remove tumor tissue, among many other applications.
Andrew Mesecar, Distinguished Professor of Biochemistry and the Walther Professor in Cancer Structural Biology, was named assistant vice president for research and director of the Purdue Institute for Cancer Research after serving, since Aug. 2022, as interim director. Mesecar was chosen for the position after a nationwide search.
Bradley Monk was named medical director of late-phase clinical research at Florida Cancer Specialists & Research Institute, LLC. Monks plans to leverage his experience and leadership across all tumor types as FCS expands in footprint in late-phase practice changing clinical trials.
